Profil
Alex Stojanovic has worked as the Chief Operating Officer at Oncolyze, Inc. since 2019.
Postes actifs de Alex Stojanovic
| Sociétés | Poste | Début |
|---|---|---|
Oncolyze, Inc.
 Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Directeur des opérations | 01/01/2019 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Health Technology |
